Oncology
14 years
Dr. Amit Ghanekar is a Consultant Medical Oncologist at Fortis Hospital, Kalyan, Maharashtra. His clinical expertise includes the diagnosis and medical treatment of cancers, particularly blood-related malignancies, and the management of patients who may require bone marrow or stem cell transplantation.
He holds MBBS, MD in Internal Medicine and DNB in Medical Oncology qualifications. His medical training includes Lokmanya Tilak Municipal Medical College and Sion Hospital, Mumbai, B. J. Medical College and Sassoon Hospital, Pune, and Jaslok Hospital and Research Centre, Mumbai.
Dr. Ghanekar completed fellowship training in Haemato-Oncology and Bone Marrow Transplantation at Prince Aly Khan Hospital, Mumbai. He is also listed as an ESMO Certified Medical Oncologist, reflecting additional professional certification in cancer medicine.
His documented areas of expertise include leukaemia, lymphoma, multiple myeloma and other haematological malignancies. Medical oncology care may involve systemic treatment such as chemotherapy, targeted therapy or immunotherapy, depending on the cancer type and individual patient factors.
Dr. Ghanekar has experience with bone marrow and stem cell transplantation in the treatment of selected blood cancers and other serious haematological conditions. His Fortis biography also describes expertise in thrombocytopenia, polycythaemia, myelodysplastic syndromes, myeloproliferative disorders and aplastic anaemia.
His professional background includes the management of solid tumours and complex blood disorders. Patients seeking consultation for cancer diagnosis, medical oncology treatment or haematological disease evaluation can enquire about Dr. Amit Ghanekar at Fortis Hospital, Kalyan, or his other confirmed practice locations.
Leukaemia is a group of cancers affecting blood-forming tissues and white blood cells. Treatment depends on the specific subtype, disease characteristics and patient health. Options may include chemotherapy, targeted medicines or stem cell transplantation.
Lymphoma is a cancer affecting cells of the lymphatic system. Diagnosis usually requires tissue examination and appropriate staging investigations. Treatment may include immunotherapy, chemotherapy, targeted medicines or other approaches depending on lymphoma type and stage.
Multiple myeloma is a cancer involving plasma cells in the bone marrow. It may affect bones, kidneys and blood cell production. Treatment can include combinations of medicines, immunotherapy and stem cell transplantation in selected patients.
Bone marrow transplantation is a treatment used for selected blood cancers and haematological disorders. It involves replacing or restoring blood-forming stem cells after specialised preparative treatment. Eligibility depends on diagnosis, disease status and overall health.
Haematopoietic stem cell transplantation involves administering blood-forming stem cells to restore marrow function after intensive treatment. Stem cells may come from the patient or a donor. The approach depends on the underlying disease and transplant suitability.
Cancer immunotherapy uses treatments designed to enhance or modify the immune system's response to cancer. Different immunotherapies work through different mechanisms. Suitability depends on cancer type, molecular characteristics and patient-specific risk factors.
Chemotherapy uses medicines to destroy or control cancer cells. It may be used alone or in combination with other treatments. Treatment selection depends on cancer type, stage, overall health and the expected benefits and risks.
Targeted therapy uses medicines that act on specific molecular features involved in cancer growth. Some treatments require biomarker testing to identify suitable patients. Availability and effectiveness vary according to cancer type and genetic characteristics.
Myelodysplastic syndromes are disorders in which the bone marrow does not produce healthy blood cells effectively. Management depends on disease risk, blood counts and symptoms. Treatment may include supportive care, medication or transplantation in selected cases.
Myeloproliferative disorders involve abnormal production of blood cells in the bone marrow. Treatment depends on the specific diagnosis and may focus on reducing clotting risk, controlling abnormal blood counts and managing symptoms.
Aplastic anaemia occurs when the bone marrow fails to produce sufficient blood cells. Diagnosis involves blood testing and often bone marrow examination. Treatment can include supportive care, immunosuppressive therapy or stem cell transplantation.
Thrombocytopenia is a reduction in the platelet count and may increase bleeding risk. Causes include medication effects, immune disorders, infections and bone marrow conditions. Treatment depends on severity, symptoms and underlying diagnosis.
Polycythaemia involves increased red blood cell concentration, which may affect blood viscosity and clotting risk. Evaluation helps determine whether the condition is primary or secondary. Management depends on the cause and associated risks.
Solid tumours arise in organs or tissues rather than primarily in blood-forming cells. Medical oncology assessment helps determine appropriate systemic treatment based on cancer type, stage, pathology and relevant biomarkers.
MBBS, MD,DNB
Medical oncology consultation, blood cancer management, leukaemia treatment, lymphoma management, multiple myeloma treatment, bone marrow transplantation, stem cell transplantation, immunotherapy, solid tumour management, thrombocytopenia evaluation, polycythaemia management
Genuine patient experiences and treatment feedback.
Quick answers to common questions about Dr. Amit Ghanekar
Yes. His Fortis biography lists leukaemia among the haematological malignancies in his clinical practice.
Yes. Both are documented areas of his medical oncology expertise.
His official profile documents experience with bone marrow and stem cell transplantation. Current transplant availability and facilities should be confirmed.
Bone marrow transplantation is a form of haematopoietic stem cell transplantation. Stem cells may be collected from bone marrow, peripheral blood or other sources.
His Fortis profile mentions immunotherapy as an area of expertise. Suitability depends on the specific cancer and clinical findings.
Contact us for personalized help or to schedule an appointment.